Medite Cancer Diagnostics (MDIT) Stock Statistics & Valuation Metrics

Medite Cancer Diagnostics has a market cap or net worth of $8.62K. The enterprise value is ―.

Medite Cancer Diagnostics has 86,196,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Medite Cancer Diagnostics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Medite Cancer Diagnostics is ―. Medite Cancer Diagnostics’s PEG ratio is ―.

In the last 12 months, Medite Cancer Diagnostics had revenue of 6.81M and earned -6.81M in profits. Earnings per share was -0.26.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Medite Cancer Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Medite Cancer Diagnostics upcoming earnings date is Aug 14, 2017, TBA (Confirmed).

Medite Cancer Diagnostics as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Medite Cancer Diagnostics has paid -487.00K in taxes.

Medite Cancer Diagnostics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Medite Cancer Diagnostics has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Medite Cancer Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―